2020年癌症的耐药性与新型疗法
Drug Resistance and Novel Therapies in Cancers in 2020.
作者信息
Wang Zhixiang
机构信息
Department of Medical Genetics, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB T6G 2H7, Canada.
出版信息
Cancers (Basel). 2023 Jan 24;15(3):717. doi: 10.3390/cancers15030717.
Abstract
After a very successful year in 2019 with 34 publications, our Topic collection "Drug Resistance and Novel Therapies in Cancers" guaranteed another productive year with the publication of 17 research articles and 4 review articles in 2020 [...].
摘要
在2019年取得了非常成功的一年，发表了34篇论文之后，我们的主题合集《癌症中的耐药性与新疗法》在2020年又发表了17篇研究论文和4篇综述文章，确保了又一个成果丰硕的年份[...]。
相似文献
1
Drug Resistance and Novel Therapies in Cancers in 2020.2020年癌症的耐药性与新型疗法
Cancers (Basel). 2023 Jan 24;15(3):717. doi: 10.3390/cancers15030717.
2
Drug Resistance and Novel Therapies in Cancers in 2019.2019年癌症中的耐药性与新型疗法
Cancers (Basel). 2021 Feb 23;13(4):924. doi: 10.3390/cancers13040924.
3
Taking the next step in publication productivity analysis in pediatric neurosurgery.迈向小儿神经外科出版生产力分析的下一步。
J Neurosurg Pediatr. 2018 Jun;21(6):655-665. doi: 10.3171/2018.1.PEDS17535. Epub 2018 Mar 23.
4
[Bibliometric analysis of publications pertaining to artemisinin resistance in based on Web of Science from 2011 to 2022].[基于科学网对2011年至2022年期间青蒿素耐药性相关出版物的文献计量分析]
Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi. 2022 Dec 5;34(6):639-645. doi: 10.16250/j.32.1374.2022170.
5
Scientific landscape and trend analysis of keloid research: a 30-year bibliometric review.瘢痕疙瘩研究的科学态势与趋势分析：一项30年的文献计量学综述
Ann Transl Med. 2021 Jun;9(11):945. doi: 10.21037/atm-21-508.
6
Publication Trends of Research on Gallbladder Cancer During 2001-2021: A 20-Year Bibliometric Analysis.2001 - 2021年胆囊癌研究的出版趋势：一项20年的文献计量分析
Front Oncol. 2022 Jul 11;12:932797. doi: 10.3389/fonc.2022.932797. eCollection 2022.
7
Publication activity in the field of Sjögren's syndrome: a ten-year Web of Science based analysis.干燥综合征领域的发表活动：基于 Web of Science 的十年分析。
Rheumatol Int. 2021 Apr;41(4):763-769. doi: 10.1007/s00296-020-04714-1. Epub 2020 Oct 8.
8
9
A Review of COVID-19-Related Publications and Lag Times During the First Six Months of the Year 2020.2020 年上半年 COVID-19 相关文献及滞后时间综述。
West J Emerg Med. 2021 Jun 29;22(4):958-962. doi: 10.5811/westjem.2021.3.51737.
10
Performance of highly cited multiple sclerosis publications in the Science Citation Index expanded: A scientometric analysis.高被引多发性硬化症文献在《科学引文索引扩展版》中的表现：一项科学计量分析。
Mult Scler Relat Disord. 2021 Sep;54:103112. doi: 10.1016/j.msard.2021.103112. Epub 2021 Jun 30.
本文引用的文献
1
Bruton's Tyrosine Kinase Inhibitors Ibrutinib and Acalabrutinib Counteract Anthracycline Resistance in Cancer Cells Expressing AKR1C3.布鲁顿酪氨酸激酶抑制剂依鲁替尼和阿卡拉布替尼可抵消表达AKR1C3的癌细胞对蒽环类药物的耐药性。
Cancers (Basel). 2020 Dec 11;12(12):3731. doi: 10.3390/cancers12123731.
2
Getting Lost in the Cell-Lysosomal Entrapment of Chemotherapeutics.化疗药物在细胞溶酶体中的滞留困境
Cancers (Basel). 2020 Dec 7;12(12):3669. doi: 10.3390/cancers12123669.
3
Cannabidiol (CBD) as a Promising Anti-Cancer Drug.大麻二酚（CBD）作为一种有前景的抗癌药物。
Cancers (Basel). 2020 Oct 30;12(11):3203. doi: 10.3390/cancers12113203.
4
Time-Resolved Profiling Reveals ATF3 as a Novel Mediator of Endocrine Resistance in Breast Cancer.时间分辨分析揭示ATF3是乳腺癌内分泌抵抗的新型介质。
Cancers (Basel). 2020 Oct 11;12(10):2918. doi: 10.3390/cancers12102918.
5
L-Arginine/Nitric Oxide Pathway Is Altered in Colorectal Cancer and Can Be Modulated by Novel Derivatives from Oxicam Class of Non-Steroidal Anti-Inflammatory Drugs.L-精氨酸/一氧化氮途径在结直肠癌中发生改变，且可被非甾体抗炎药昔康类的新型衍生物调节。
Cancers (Basel). 2020 Sep 11;12(9):2594. doi: 10.3390/cancers12092594.
6
Electroporation-Based Treatments in Urology.泌尿外科中基于电穿孔的治疗方法
Cancers (Basel). 2020 Aug 7;12(8):2208. doi: 10.3390/cancers12082208.
7
Cisplatin Decreases ENaC Activity Contributing to Renal Salt Wasting Syndrome.顺铂降低ENaC活性，导致肾性盐耗竭综合征。
Cancers (Basel). 2020 Aug 1;12(8):2140. doi: 10.3390/cancers12082140.
8
Mambalgin-2 Induces Cell Cycle Arrest and Apoptosis in Glioma Cells via Interaction with ASIC1a.曼巴精-2通过与酸敏感离子通道1a相互作用诱导胶质瘤细胞的细胞周期停滞和凋亡。
Cancers (Basel). 2020 Jul 8;12(7):1837. doi: 10.3390/cancers12071837.
9
Erdafitinib Resensitizes ABCB1-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs.厄达替尼使过表达ABCB1的多药耐药癌细胞对细胞毒性抗癌药物重新敏感。
Cancers (Basel). 2020 May 26;12(6):1366. doi: 10.3390/cancers12061366.
10
Chemotherapeutic Agents Sensitize Resistant Cancer Cells to the DR5-Specific Variant DR5-B more Efficiently than to TRAIL by Modulating the Surface Expression of Death and Decoy Receptors.化疗药物通过调节死亡受体和诱饵受体的表面表达，使耐药癌细胞对DR5特异性变体DR5-B的敏感性高于对TRAIL的敏感性。
Cancers (Basel). 2020 Apr 30;12(5):1129. doi: 10.3390/cancers12051129.
Zotero 插件